|Bid||53.19 x 800|
|Ask||54.31 x 900|
|Day's range||54.16 - 54.52|
|52-week range||36.91 - 58.10|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||15.20|
|Forward dividend & yield||1.90 (3.50%)|
|Ex-dividend date||25 May 2023|
|1y target est||63.50|
On March 23, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD). Let's take a look at the clinical data and the global COPD market to assess the sales potential of the drug.
Availability of the Q1 2023 Memorandum for modelling purposes Paris, France – March 30, 2023 - Sanofi announced today that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q1-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various no
Sanofi (SNY) closed at $53.22 in the latest trading session, marking a +1.16% move from the prior day.